Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone

@article{Jeffery2004TreatmentOM,
  title={Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone},
  author={Douglas R. Jeffery and David S. Lefkowitz and J. Crittenden},
  journal={Journal of Neuroimaging},
  year={2004},
  volume={14}
}
Marburg variant multiple sclerosis (MS) is a severe, sometimes monophasic, form of MS leading to advanced disability or death within a period of weeks to months. No consistently successful treatment for Marburg variant MS has been described. The case reported here is that of a 34‐year‐old woman with Marburg variant MS whose magnetic resonance imaging scan showed extensive brainstem, periventricular white matter, subcortical, and cortical involvement, giving the appearance of an “MS cerebritis… 

Marburg Multiple Sclerosis Variant: Complete Remission with Very Early Administration of Mitoxantrone—A Case Report

The inflammatory explosive case of a 31-year-old woman presenting with rapid neurological degradation of histology proven Marburg’s disease, successfully treated with early administration of Mitoxantrone (MITX), which is the first case describing complete remission after MITX in a biopsy-proven condition.

Long survival and clinical stability in Marburg’s variant multiple sclerosis

The patient reached clinical stability with severe residual disability, persistent after 3 years from onset, suggests that subjects with Marburg’s MS might reach long clinical stability.

A second case of Marburg’s variant of multiple sclerosis with vasculitis and extensive demyelination

A case of a 31-year-old woman with Marburg’s variant of MS who, over a period of eight months, became totally disabled, blind, and quadriplegic, with vocal cord paralysis, requiring a tracheostomy is reported.

Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue

HiCy rescue treatment followed by ocrelizumab as a maintenance therapy prevented permanent disability and achieved an almost complete clinical and drastic radiological improvement in this Marburg MS patient.

Marburg variant of multiple sclerosis; a diagnostic and therapeutic challenge

A 35 years old male who presented with rapidly progressive demyelinating illness, leading to bed bound status over the course of a month was treated aggressively with intravenous (IV) steroids, plasma exchange (PLEX) and Mitoxantrone (MTX), leading to a remarkable recovery.

High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report

Marburg's Variant of Multiple Sclerosis with Extensive Brain Lesions: An Autopsy Case Report

Even when marked improvement following IV methylprednisolone is observed, adjunct therapy with a second modality should be considered to improve the chance of survival.

Enfermedad de Marburg como variante de esclerosis múltiple: presentación de un caso atípico

A 58 years old woman with multiple sclerosis diagnosed in 2007 is presented, she was treated with interferon and methylprednisolone with a stable disease until last year, when she developed a distributive shock leading to death.

Marburg type and Balò’s concentric sclerosis: rare and acute variants of multiple sclerosis

These forms now can be diagnosed in vivo, with complete clinical and laboratory examination and MRI follow up, and the poor prognosis of the majority of these cases justifies a treatment with intense immunosuppression.

An autopsy case of the Marburg variant of multiple sclerosis (acute multiple sclerosis).

The autopsy revealed multiple inflammatory demyelinating lesions in the central nervous system of the Marburg variant of multiple sclerosis, and two noteworthy histopathological features were observed compared with prototypical MS.
...

References

SHOWING 1-10 OF 14 REFERENCES

Fulminant monophasic multiple sclerosis, Marburg's type.

The clinical, neuroradiological and necropsy findings are described in a 49 year old woman with long-standing idiopathic pulmonary haemosiderosis and acute monophasic multiple sclerosis (Marburg's type) who died 10 weeks after onset of symptoms.

Treatment of multiple sclerosis with mitoxantrone

It appears that mitoxantrone accelerates the disappearance of Gd-enhancing lesions and prevents the development of new ones in multiple sclerosis patients with rapid deteriorating disease profile.

Malignant monophasic multiple sclerosis or “Marburg's disease"

Newimaging showed progressive white matter attenuation, and newpathology was characteristic of multiple sclerosis, leading to death 29 days after onset in a patient with an acute monophasic demyelinating disease.

Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination

Results of this uncontrolled study suggest that plasmapheresis in the absence of other immunosuppressive drugs may have a role in the treatment of severe episodes of inflammatory demyelination in a select subset of MS patients.

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

In this selected group of patients with multiple sclerosis with very active disease, mitoxantrone combined with methylprednisolone was effective in improving both clinical and MRI indices of disease activity over a period of six months whereas methylpredisonsolone alone was not.

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease

Plasma exchange leads to functionally important neurological recovery in an important proportion of severely disabled patients with acute attacks of idiopathic inflammatory demyelinating disease, and was sustained on follow‐up.

Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.

Flow cytometric analysis revealed a dramatic decrease in splenic B lymphocyte content, and mitoxantrone exerted a potent suppressive influence on the humoral immune system through a direct reduction in B cell number augmented by macrophage-mediated inhibition of B cell proliferation.

Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.

The macrophage-mediated suppression of TH cell induction and humoral immunity investigated in spleens from mitoxantrone-treated mice is an intriguing finding that may have significant implications for immunotherapy.